Empagliflozin (BioDeep_00000015054)
代谢物信息卡片
Empagliflozin (BI 10773)
化学式: C23H27ClO7 (450.14452220000004)
中文名称: 依帕列净
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
InChI: InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
2 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:82720
- KEGG: C22194
- KEGGdrug: D10459
- PubChem: 11949646
- DrugBank: DB09038
- ChEMBL: CHEMBL2107830
- CAS: 864070-44-0
- PubChem: 405226385
- PDB-CCD: 7R3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lakshmi Vineela Nalla, Amit Khairnar. Empagliflozin drives ferroptosis in anoikis-resistant cells by activating miR-128-3p dependent pathway and inhibiting CD98hc in breast cancer.
Free radical biology & medicine.
2024 Aug; 220(?):288-300. doi:
10.1016/j.freeradbiomed.2024.05.018. [PMID: 38734268] - Silvie Hojná, Hana Malínská, Martina Hüttl, Zdeňka Vaňourková, Irena Marková, Denisa Miklánková, Jaroslav Hrdlička, František Papoušek, Jan Neckář, Petr Kujal, Michal Behuliak, Hana Rauchová, Michaela Kadlecová, David Sedmera, Kristýna Neffeová, Eva Zábrodská, Veronika Olejníčková, Josef Zicha, Ivana Vaněčková. Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2024 May; 174(?):116520. doi:
10.1016/j.biopha.2024.116520. [PMID: 38581924] - Isabella Bonilha, Érica Ivana Lázaro Gomes, Helison R P Carmo, Ikaro Breder, Joaquim Barreto, Jessica Breder, Daniel B Munhoz, Luiz Sergio F Carvalho, Thiago Quinaglia, Sheila T Kimura-Medorima, Camila Moreira Gossi, Francesca Zimetti, Wilson Nadruz, Ilaria Zanotti, Andrei C Sposito. Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial.
International journal of molecular sciences.
2024 Apr; 25(7):. doi:
10.3390/ijms25074108. [PMID: 38612917] - Abdullah Shoaib, Sammia Shahid, Sana Mansoor, Mohsin Javed, Shahid Iqbal, Sajid Mahmood, Ali Bahadur, Fadi Jaber, Matar Alshalwi. Tailoring of an anti-diabetic drug empagliflozin onto zinc oxide nanoparticles: characterization and in vitro evaluation of anti-hyperglycemic potential.
Scientific reports.
2024 01; 14(1):2499. doi:
10.1038/s41598-024-52523-4. [PMID: 38291095] - Roopameera Thirumathyam, Erik Arne Richter, Gerrit van Hall, Jens Juul Holst, Mogens Fenger, Jens P Gøtze, Ulrik Dixen, Niels Vejlstrup, Sten Madsbad, Per Lav Madsen, Nils Bruun Jørgensen. The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator.
Cardiovascular diabetology.
2024 01; 23(1):13. doi:
10.1186/s12933-023-02094-x. [PMID: 38184612] - Anil Kumar Goud Thallapalli, Ram Mohan Manda. Development and validation of Empagliflozin and Linagliptin simultaneous estimation in rat plasma using freezing lipid precipitation and SCX-SPE assisted HPLC-MS/MS method and its application in pharmacokinetic studies.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2024 Jan; 40(1):185-198. doi:
10.1007/s44211-023-00444-z. [PMID: 37921942] - Qiong Yang, Ling Deng, Changmei Feng, Jianghua Wen. Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
PeerJ.
2024; 12(?):e17055. doi:
10.7717/peerj.17055. [PMID: 38500527] - Yu-Hao Lin, Zhi-Jun Zhang, Jin-Qing Zhong, Zhi-Yi Wang, Yi-Ting Peng, Yan-Mei Lin, Huo-Ping Zhang, Jian-Qing Tian. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
PloS one.
2024; 19(5):e0302155. doi:
10.1371/journal.pone.0302155. [PMID: 38701096] - Laya Hooshmand Gharabagh, Ali Shargh, Mohammad Reza Mohammad Hosseini Azar, Ayda Esmaeili. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Clinics and research in hepatology and gastroenterology.
2023 Dec; 48(3):102279. doi:
10.1016/j.clinre.2023.102279. [PMID: 38159676] - Chuangbiao Zhang, Beibei Zhu, Youzhen Feng, Zhongyuan Cheng, Xiangran Cai, Lie Feng, Jiaying Li, Xiaohua Lu. Assessing early tubular protective effects of SGLT2 inhibitor empagliflozin against type 2 diabetes mellitus using functional magnetic resonance imaging.
Acta diabetologica.
2023 Dec; ?(?):. doi:
10.1007/s00592-023-02220-x. [PMID: 38117325] - Abdulrahman Mujalli, Wesam F Farrash, Ahmad A Obaid, Anmar A Khan, Riyad A Almaimani, Shakir Idris, Mohamed E Elzubier, Elshiekh Babiker A Khidir, Akhmed Aslam, Faisal Minshawi, Mohammad A Alobaidy, Adel B Alharbi, Hussain A Almasmoum, Mazen Ghaith, Khalid Alqethami, Bassem Refaat. Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus.
International journal of molecular sciences.
2023 Dec; 24(24):. doi:
10.3390/ijms242417380. [PMID: 38139208] - Zahra Vaziri, Kiarash Saleki, Cena Aram, Parsa Alijanizadeh, Ramtin Pourahmad, Abbas Azadmehr, Naghmeh Ziaei. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2023 Dec; 168(?):115686. doi:
10.1016/j.biopha.2023.115686. [PMID: 37839109] - Noha Nabil Mohammed, Mariane G Tadros, Mina Y George. Empagliflozin repurposing in Parkinson's disease; modulation of oxidative stress, neuroinflammation, AMPK/SIRT-1/PGC-1α, and wnt/β-catenin pathways.
Inflammopharmacology.
2023 Dec; ?(?):. doi:
10.1007/s10787-023-01384-w. [PMID: 38038781] - Mohamed M Elseweidy, Abd El-Monem Ali, Sara M Hassanin, Yasmin K Mahmoud. Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-κB/SOX9/OPN signaling and osteocalcin level.
Naunyn-Schmiedeberg's archives of pharmacology.
2023 Nov; ?(?):. doi:
10.1007/s00210-023-02826-6. [PMID: 37962587] - Manal Moustafa Mahmoud, Laila Ahmed Rashed, Somia Abdulatif Soliman, Safaa Mostafa Sayed, Omneya Kamel, Samaa Samir Kamar, Rania El Sayed Hussien. SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model.
Physiological reports.
2023 Nov; 11(22):e15858. doi:
10.14814/phy2.15858. [PMID: 37985173] - Ting Wu, Zhiqin Zhang, Haowen Huang, Xiaoyan Wu. RNA-Seq Analysis of ceRNA-Related Networks in the Regulatory Metabolic Pathway of Mice with Diabetic Nephropathy Subjected to Empagliflozin Intervention.
Archivos espanoles de urologia.
2023 Nov; 76(9):680-689. doi:
10.56434/j.arch.esp.urol.20237609.83. [PMID: 38053423] - Lucia Scisciola, Ugo Chianese, Vicky Caponigro, Manuela Giovanna Basilicata, Emanuela Salviati, Lucia Altucci, Pietro Campiglia, Giuseppe Paolisso, Michelangela Barbieri, Rosaria Benedetti, Eduardo Sommella. Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes.
Journal of translational medicine.
2023 09; 21(1):662. doi:
10.1186/s12967-023-04537-1. [PMID: 37742032] - Wei Yu, Lin Wang, Wei-Ying Ren, Hai-Xia Xu, Ne N Wu, Dong-Hui Yu, Russel J Reiter, Wen-Liang Zha, Qing-Dong Guo, Jun Ren. SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson's disease.
Acta pharmacologica Sinica.
2023 Sep; ?(?):. doi:
10.1038/s41401-023-01144-0. [PMID: 37679644] - Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H-H Sheu, Cheli Melzer-Cohen, Reinhard W Holl, Júlio Núñez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nyström, Leo Niskanen, Sonia Guleria, Riho Klement, Marc Carrasco, Johannes Foersch, Christina Shay, Lisette Koeneman, Fabian Hoti, Soulmaz Fazeli Farsani, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Cardiovascular diabetology.
2023 08; 22(1):233. doi:
10.1186/s12933-023-01963-9. [PMID: 37653496] - Fangyan Tan, Xianglin Long, Jianlin Du, Xin Yuan. RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2023 Aug; 166(?):115289. doi:
10.1016/j.biopha.2023.115289. [PMID: 37572641] - Edoardo Biancalana, Chiara Rossi, Francesco Raggi, Mariarosaria Distaso, Domenico Tricò, Simona Baldi, Ele Ferrannini, Anna Solini. Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects.
The Journal of clinical endocrinology and metabolism.
2023 Jul; 108(8):e567-e573. doi:
10.1210/clinem/dgad088. [PMID: 36794422] - Shigenori Hiruma, Fumika Shigiyama, Naoki Kumashiro. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study.
Diabetes, obesity & metabolism.
2023 06; 25(6):1576-1588. doi:
10.1111/dom.15006. [PMID: 36749298] - Mengyuan Ge, Judith Molina, Jin-Ju Kim, Shamroop K Mallela, Anis Ahmad, Javier Varona Santos, Hassan Al-Ali, Alla Mitrofanova, Kumar Sharma, Flavia Fontanesi, Sandra Merscher, Alessia Fornoni. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome.
eLife.
2023 05; 12(?):. doi:
10.7554/elife.83353. [PMID: 37129368] - Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee. Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2023 May; 161(?):114445. doi:
10.1016/j.biopha.2023.114445. [PMID: 36842353] - Z Dogan, D D Ergun, S Durmus, H Sahin, G E Senturk, R Gelisgen, A Senyigit, H Uzun. Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes - the role of morphology of mitochondria observed on electron microscopy.
European review for medical and pharmacological sciences.
2023 05; 27(9):3979-3992. doi:
10.26355/eurrev_202305_32304. [PMID: 37203822] - Shih-Jie Jhuo, Yi-Hsiung Lin, I-Hsin Liu, Tsung-Hsien Lin, Bin-Nan Wu, Kun-Tai Lee, Wen-Ter Lai. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling.
International journal of molecular sciences.
2023 Apr; 24(7):. doi:
10.3390/ijms24076842. [PMID: 37047815] - Avraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H-H Sheu, Cheli Melzer-Cohen, Reinhard W Holl, Kyoung Hwa Ha, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Thomas Nyström, Leo Niskanen, Majken Linnemann Jensen, Fabian Hoti, Riho Klement, Anouk Déruaz-Luyet, Moe H Kyaw, Lisette Koeneman, Dorte Vistisen, Bendix Carstensen, Sigrun Halvorsen, Gisle Langslet, Soulmaz Fazeli Farsani, Elisabetta Patorno, Júlio Núñez. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes & metabolism.
2023 03; 49(2):101418. doi:
10.1016/j.diabet.2022.101418. [PMID: 36608816] - Niels H Brandt-Jacobsen, Mikkel Jürgens, Philip Hasbak, Peter Gaede, Peter Rossing, Jon J Rasmussen, Camillla Fuchs Andersen, Julie L Forman, Jens Faber, Silvio E Inzucchi, Finn Gustafsson, Morten Schou, Caroline Kistorp. Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial.
Diabetes, obesity & metabolism.
2023 03; 25(3):844-855. doi:
10.1111/dom.14933. [PMID: 36484428] - Emil List Larsen, Andreas Andersen, Laura K Kjær, Mie K Eickhoff, Marie Frimodt-Møller, Frederik Persson, Peter Rossing, Jens Lykkesfeldt, Filip K Knop, Tina Vilsbøll, Jørgen Rungby, Henrik E Poulsen. Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials.
Free radical research.
2023 Feb; 57(2):140-151. doi:
10.1080/10715762.2023.2213820. [PMID: 37171199] - QianYu Lu, LiJiao Yang, Jing-Jie Xiao, Qing Liu, LiHua Ni, Jun-Wei Hu, Hong Yu, XiaoYan Wu, Bai-Fang Zhang. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway.
Free radical biology & medicine.
2023 02; 195(?):89-102. doi:
10.1016/j.freeradbiomed.2022.12.088. [PMID: 36581059] - Jie Min, Lin Wu, Yandong Liu, Guoliang Song, Qinqin Deng, Wei Jin, Wei Yu, Miyesaier Abudureyimu, Zhaohui Pei, Jun Ren. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis.
Life sciences.
2023 Jan; 312(?):121207. doi:
10.1016/j.lfs.2022.121207. [PMID: 36403642] - Yi Wang, Qi-Ling Shen, Qi Xin, Bei Sun, Shi Zhang, Qian-Hua Fang, Ying-Xin Shi, Wen-Yan Niu, Jing-Na Lin, Chun-Jun Li. MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH.
Journal of molecular endocrinology.
2022 10; 69(3):415-430. doi:
10.1530/jme-22-0022. [PMID: 35900373] - Ephraim B Winzer, Antje Schauer, Erik Langner, Antje Augstein, Keita Goto, Anita Männel, Peggy Barthel, Anett Jannasch, Siegfried Labeit, Norman Mangner, Axel Linke, Volker Adams. Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.
International journal of molecular sciences.
2022 Sep; 23(19):. doi:
10.3390/ijms231910989. [PMID: 36232292] - Xing Chen, Shuchun Chen, Qingjuan Ren, Shu Niu, Lin Yue, Xiaoyu Pan, Zelin Li, Ruiyi Zhu, Zhuoya Jia, Xiaoyi Chen, Ruoxi Zhen, Jiangli Ban. A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice.
Biochemical and biophysical research communications.
2022 09; 621(?):122-129. doi:
10.1016/j.bbrc.2022.06.091. [PMID: 35820282] - Surabhi Bangarbale, Blythe D Shepard, Shivani Bansal, Meth M Jayatilake, Ryan Kurtz, Moshe Levi, Carolyn M Ecelbarger. Renal Metabolome in Obese Mice Treated with Empagliflozin Suggests a Reduction in Cellular Respiration.
Biomolecules.
2022 08; 12(9):. doi:
10.3390/biom12091176. [PMID: 36139016] - Roopameera Thirumathyam, Erik Arne Richter, Jens Peter Goetze, Mogens Fenger, Gerrit Van Hall, Ulrik Dixen, Jens Juul Holst, Sten Madsbad, Niels Vejlstrup, Per Lav Madsen, Nils Bruun Jørgensen. Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial.
BMJ open.
2022 08; 12(8):e054100. doi:
10.1136/bmjopen-2021-054100. [PMID: 35953245] - Kirsten Thiele, Matthias Rau, Niels-Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.
ESC heart failure.
2022 08; 9(4):2233-2238. doi:
10.1002/ehf2.13955. [PMID: 35611683] - Qiaoyun Gong, Rulin Zhang, Fang Wei, Junwei Fang, Jingfa Zhang, Jun Sun, Qian Sun, Haiyan Wang. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Aug; 152(?):113222. doi:
10.1016/j.biopha.2022.113222. [PMID: 35671581] - Giovanna B Carpentieri, Sandra E A B Gonçalves, Mayra Z Casagrande, Walid M Mourad, Lara G C Pinto, Maria Teresa Zanella. SGLT2 Inhibition with Empagliflozin as a Possible Therapeutic Option for Postprandial Hypoglycemia After Bariatric Surgery.
Obesity surgery.
2022 Aug; 32(8):2664-2671. doi:
10.1007/s11695-022-06119-4. [PMID: 35674979] - Dina E Al-Wakeel, Dalia H El-Kashef, Manar A Nader. Renoprotective effect of empagliflozin in cafeteria diet-induced insulin resistance in rats: Modulation of HMGB-1/TLR-4/NF-κB axis.
Life sciences.
2022 Jul; 301(?):120633. doi:
10.1016/j.lfs.2022.120633. [PMID: 35568226] - Domenico Tricò, Francesco Raggi, Mariarosaria Distaso, Ele Ferrannini, Anna Solini. Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.
Diabetes research and clinical practice.
2022 Jul; 190(?):109983. doi:
10.1016/j.diabres.2022.109983. [PMID: 35803317] - Satilmis Bilgin, Tuba Taslamacioglu Duman, Ozge Kurtkulagi, Feyza Yilmaz, Gulali Aktas. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.
2022 Jul; 32(7):928-930. doi:
10.29271/jcpsp.2022.07.928. [PMID: 35795946] - Peter Manu. Drug Therapy for Unexplained Dyspnea in Post-COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil.
American journal of therapeutics.
2022 07; 29(4):e447-e448. doi:
10.1097/mjt.0000000000001483. [PMID: 35412483] - Rajiv Agarwal, Sibylle Jenny Hauske, David C Wheeler, Kent Doi, Amelie Elsaesser, Ivana Ritter, Dominik Steubl, Christoph Wanner. Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.
Diabetes, obesity & metabolism.
2022 07; 24(7):1390-1393. doi:
10.1111/dom.14694. [PMID: 35302277] - Xinru Deng, Chenhong Zhang, Pengxu Wang, Wei Wei, Xiaoyang Shi, Pingping Wang, Junpeng Yang, Limin Wang, Shasha Tang, Yuanyuan Fang, Yalei Liu, Yiqi Chen, Yun Zhang, Qian Yuan, Jing Shang, Quane Kan, Huihui Yang, Hua Man, Danyu Wang, Huijuan Yuan. Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism.
2022 06; 107(7):1888-1896. doi:
10.1210/clinem/dgac210. [PMID: 35397165] - Priyadarshini Balasubramanian, Christoph Wanner, João Pedro Ferreira, Anne Pernille Ofstad, Amelie Elsaesser, Bernard Zinman, Silvio E Inzucchi. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?.
The Journal of clinical endocrinology and metabolism.
2022 Jun; 107(7):e3003-e3007. doi:
10.1210/clinem/dgac154. [PMID: 35290464] - Jennifer B Green, Amy K Mottl, George Bakris, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE).
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2022 Jun; ?(?):. doi:
10.1093/ndt/gfac198. [PMID: 35700142] - Katherine R Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C Wheeler. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Diabetes care.
2022 06; 45(6):1445-1452. doi:
10.2337/dc21-2034. [PMID: 35472672] - Odette S Reifsnider, Anuraag R Kansal, Christoph Wanner, Egon Pfarr, Audrey Koitka-Weber, Sarah B Brand, Matthew Stargardter, Cheng Wang, Effie Kuti, Anastasia Ustyugova. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2022 06; 79(6):796-806. doi:
10.1053/j.ajkd.2021.09.014. [PMID: 34752913] - Dusan Harmacek, Menno Pruijm, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Olivier Bonny, Anne Zanchi. Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.
Journal of the American Society of Nephrology : JASN.
2022 06; 33(6):1073-1075. doi:
10.1681/asn.2021111515. [PMID: 35387874] - Annika Khine, Jonas Kwok, Eugene Lin. Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2022 06; 79(6):780-782. doi:
10.1053/j.ajkd.2021.11.003. [PMID: 35115191] - Ryan Kurtz, Andrew Libby, Bryce A Jones, Komuraiah Myakala, Xiaoxin Wang, Yichien Lee, Grace Knoer, Julia N Lo Cascio, Michaela McCormack, Grace Nguyen, Elijah N D Choos, Olga Rodriguez, Avi Z Rosenberg, Suman Ranjit, Christopher Albanese, Moshe Levi, Carolyn M Ecelbarger, Blythe D Shepard. Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice.
International journal of molecular sciences.
2022 May; 23(10):. doi:
10.3390/ijms23105675. [PMID: 35628485] - Ryoichi Miyazaki, Kyoko Miyagi. Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases.
BMC nephrology.
2022 05; 23(1):168. doi:
10.1186/s12882-022-02793-9. [PMID: 35501824] - Stefan D Anker, Leif-Erik Sander, David H Fitchett, Bernard Zinman, Anne Pernille Ofstad, Christoph Wanner, Ola Vedin, Sabine Lauer, Subodh Verma, Henry K Yaggi, Silvio E Inzucchi. Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
Diabetes research and clinical practice.
2022 Apr; 186(?):109837. doi:
10.1016/j.diabres.2022.109837. [PMID: 35314257] - João Pedro Ferreira, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Tomoko Iwata, Afshin Salsali, Cordula Zeller, Stuart J Pocock, Faiez Zannad, Milton Packer. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
European journal of heart failure.
2022 Apr; 24(4):708-715. doi:
10.1002/ejhf.2409. [PMID: 34957660] - Jennifer Matthews, Lakshini Herat, Jennifer Rooney, Elizabeth Rakoczy, Markus Schlaich, Vance B Matthews. Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy.
Bioscience reports.
2022 03; 42(3):. doi:
10.1042/bsr20212209. [PMID: 35234250] - Simeon Schietzel, Lia Bally, Grazia Cereghetti, Nicolas Faller, Matthias B Moor, Bruno Vogt, Felix Rintelen, S Trelle, Daniel Fuster. Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.
BMJ open.
2022 03; 12(3):e059073. doi:
10.1136/bmjopen-2021-059073. [PMID: 35288397] - Roxana Pérez-Villavicencio, Javier Flores-Estrada, Martha Franco, Bruno Escalante, Oscar Pérez-Méndez, Adriana Mercado, Rocio Bautista-Pérez. Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats.
International journal of molecular sciences.
2022 Mar; 23(5):. doi:
10.3390/ijms23052883. [PMID: 35270028] - Luis M Pérez-Belmonte, Jaime Sanz-Cánovas, Mercedes Millán-Gómez, Julio Osuna-Sánchez, Almudena López-Sampalo, Michele Ricci, Manuel Jiménez-Navarro, Maria D López-Carmona, María Rosa Bernal-López, Miguel A Barbancho, José P Lara, Ricardo Gómez-Huelgas. Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Journal of the American Geriatrics Society.
2022 03; 70(3):862-871. doi:
10.1111/jgs.17585. [PMID: 34843628] - Qian Wu, Miaowen Liu, Zige Fang, Chenxi Li, Fang Zou, Lei Hu, Wenxiong Zhang. Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials.
Journal of clinical pharmacy and therapeutics.
2022 Mar; 47(3):270-286. doi:
10.1111/jcpt.13521. [PMID: 34544199] - Elisabetta Patorno, Ajinkya Pawar, Deborah J Wexler, Robert J Glynn, Lily G Bessette, Julie M Paik, Mehdi Najafzadeh, Kimberly G Brodovicz, Anouk Déruaz-Luyet, Sebastian Schneeweiss. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes, obesity & metabolism.
2022 03; 24(3):442-454. doi:
10.1111/dom.14593. [PMID: 34729891] - Dou Huang, Feng Ju, Lei Du, Ting Liu, Yunxia Zuo, Geoffrey W Abbott, Zhaoyang Hu. Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism.
The Journal of pharmacology and experimental therapeutics.
2022 03; 380(3):230-241. doi:
10.1124/jpet.121.000956. [PMID: 34893552] - Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Videbæk, Christian Tuxen, Julie H Larsen, Camilla F Andersen, Finn Gustafsson, Lars Køber, Morten Schou, Jacob Eifer Møller. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Cardiovascular diabetology.
2022 02; 21(1):34. doi:
10.1186/s12933-022-01463-2. [PMID: 35219331] - Shufei Zeng, Denis Delic, Chang Chu, Yingquan Xiong, Ting Luo, Xiaoyi Chen, Mohamed M S Gaballa, Yao Xue, Xin Chen, Yaochen Cao, Ahmed A Hasan, Kai Stadermann, Sandra Frankenreiter, Lianghong Yin, Bernhard K Krämer, Thomas Klein, Berthold Hocher. Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Feb; 146(?):112606. doi:
10.1016/j.biopha.2021.112606. [PMID: 34968924] - Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F Fromm, Roland E Schmieder, Renke Maas. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Cardiovascular diabetology.
2022 01; 21(1):4. doi:
10.1186/s12933-021-01436-x. [PMID: 34991562] - Juliana Cordovil Cotrin, Gabriel Santos Martins de Souza, Tamiris Ingrid Petito-da-Silva, Luiz Eduardo Macedo Cardoso, Vanessa Souza-Mello, Sandra Barbosa-da-Silva. Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
2022; 2022(?):8861911. doi:
10.1155/2022/8861911. [PMID: 35111238] - Santenna Chenchula, Shoban Babu Varthya, R Padmavathi. Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Current diabetes reviews.
2022; 18(4):e100921196392. doi:
10.2174/1573399817666210910165402. [PMID: 34514991] - Ai-Yu Yang, Hung-Chun Chen. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
Journal of diabetes research.
2022; 2022(?):2420857. doi:
10.1155/2022/2420857. [PMID: 35656359] - Parisa Dana, Nasim Hayati Roodbari, Parichehreh Yaghmaei, Zahra Hajebrahimi. Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats.
Frontiers in endocrinology.
2022; 13(?):1059942. doi:
10.3389/fendo.2022.1059942. [PMID: 36479221] - Moein Ala, Mohammad Reza Fallahpour Khoshdel, Ahmad Reza Dehpour. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
Oxidative medicine and cellular longevity.
2022; 2022(?):1197061. doi:
10.1155/2022/1197061. [PMID: 35126806] - Nasrin Shakerinasab, Mahdokht Azizi, Mahboubeh Mansourian, Hossein Sadeghi, Shirvan Salaminia, Reza Abbasi, Mohammad Esmaeil Shahaboddin, Amir Hossein Doustimotlagh. Empagliflozin Exhibits Hepatoprotective Effects Against Bile Duct Ligation-induced Liver Injury in Rats: A Combined Molecular Docking Approach to In Vivo Studies.
Current pharmaceutical design.
2022; 28(40):3313-3323. doi:
10.2174/1381612829666221027112239. [PMID: 36305136] - Tongtong Ye, Jingwen Zhang, Di Wu, Junfeng Shi, Zengguang Kuang, Yuting Ma, Qian Xu, Bing Chen, Chengxia Kan, Xiaodong Sun, Fang Han. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.
Frontiers in endocrinology.
2022; 13(?):907984. doi:
10.3389/fendo.2022.907984. [PMID: 35784553] - Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan, Amirhossein Sahebkar. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Journal of diabetes research.
2022; 2022(?):7520632. doi:
10.1155/2022/7520632. [PMID: 35224108] - Anna Masajtis-Zagajewska, Tomasz Hołub, Katarzyna Pęczek, Agnieszka Makówka, Michał Nowicki. Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease.
Medicina (Kaunas, Lithuania).
2021 Dec; 57(12):. doi:
10.3390/medicina57121352. [PMID: 34946298] - Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P Craven, Miroslawa Gorecka, David Broadbent, Peter Swoboda, Klaus K Witte, Richard M Cubbon, Hui Xue, Peter Kellman, John P Greenwood, Sven Plein, Eylem Levelt. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.
Diabetes.
2021 12; 70(12):2810-2822. doi:
10.2337/db21-0270. [PMID: 34610982] - Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
Diabetes research and clinical practice.
2021 Dec; 182(?):109123. doi:
10.1016/j.diabres.2021.109123. [PMID: 34740742] - Søren S Lund, Naveed Sattar, Afshin Salsali, Dietmar Neubacher, Henry N Ginsberg. Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials.
Diabetes, obesity & metabolism.
2021 12; 23(12):2763-2774. doi:
10.1111/dom.14534. [PMID: 34463415] - Silvie Hojná, Hana Rauchová, Hana Malínská, Irena Marková, Martina Hüttl, František Papoušek, Michal Behuliak, Denisa Miklánková, Zdeňka Vaňourková, Jan Neckář, Michaela Kadlecová, Petr Kujal, Josef Zicha, Ivana Vaněčková. Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Dec; 144(?):112246. doi:
10.1016/j.biopha.2021.112246. [PMID: 34601191] - David Fitchett, Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T George, Stefan Hantel, Erich Bluhmki, John M Lachin, Faiez Zannad. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
ESC heart failure.
2021 12; 8(6):4517-4527. doi:
10.1002/ehf2.13615. [PMID: 34605192] - Xiaohan Wu, He Li, Zhijie Wan, Ran Wang, Jing Liu, Qingfeng Liu, Haiyun Zhao, Zhehuan Wang, Huiru Zhang, Hui Guo, Caihong Qi, Xiangyue Jiao, Xiaotian Li. The combination of ursolic acid and empagliflozin relieves diabetic nephropathy by reducing inflammation, oxidative stress and renal fibrosis.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Dec; 144(?):112267. doi:
10.1016/j.biopha.2021.112267. [PMID: 34624679] - Kirsten Thiele, Matthias Rau, Niels-Ulrik K Hartmann, Julia Möllmann, Joachim Jankowski, Michael Böhm, András P Keszei, Nikolaus Marx, Michael Lehrke. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Diabetes, obesity & metabolism.
2021 12; 23(12):2814-2818. doi:
10.1111/dom.14517. [PMID: 34378852] - Chiang-Chi Huang, Chia-An Chou, Wei-Yu Chen, Jenq-Lin Yang, Wen-Chin Lee, Jin-Bor Chen, Chien-Te Lee, Lung-Chih Li. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice.
International journal of molecular sciences.
2021 Nov; 22(22):. doi:
10.3390/ijms222212408. [PMID: 34830289] - Hongyan Liu, Vikas S Sridhar, Daniel Montemayor, Leif Erik Lovblom, Yuliya Lytvyn, Hongping Ye, Jiwan Kim, Mir Tariq Ali, Daniel Scarr, Patrick R Lawler, Bruce A Perkins, Kumar Sharma, David Z I Cherney. Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes.
Diabetes, obesity & metabolism.
2021 11; 23(11):2466-2475. doi:
10.1111/dom.14489. [PMID: 34251085] - David Z I Cherney, Petter Bjornstad, Bruce A Perkins, Julio Rosenstock, Dietmar Neubacher, Jan Marquard, Nima Soleymanlou. Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Clinical journal of the American Society of Nephrology : CJASN.
2021 11; 16(11):1715-1719. doi:
10.2215/cjn.07700621. [PMID: 34535454] - Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
International journal of molecular sciences.
2021 Oct; 22(21):. doi:
10.3390/ijms222111513. [PMID: 34768942] - Milton Packer, Javed Butler, Faiez Zannad, Stuart J Pocock, Gerasimos Filippatos, João P Ferreira, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Christoph Wanner, Stefan D Anker. Empagliflozin and Major Renal Outcomes in Heart Failure.
The New England journal of medicine.
2021 10; 385(16):1531-1533. doi:
10.1056/nejmc2112411. [PMID: 34449179] - Stefan D Anker, Piotr Ponikowski, Christoph Wanner, Egon Pfarr, Sibylle Hauske, Barbara Peil, Afshin Salsali, Ivana Ritter, Audrey Koitka-Weber, Martina Brueckmann, JoAnn Lindenfeld, William T Abraham. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
Circulation.
2021 10; 144(15):1265-1267. doi:
10.1161/circulationaha.121.054669. [PMID: 34397263] - Karan Matharu, Kiran Chana, Charles J Ferro, Alan M Jones. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
Pharmacology research & perspectives.
2021 10; 9(5):e00867. doi:
10.1002/prp2.867. [PMID: 34586753] - Kosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru Shimizu. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
ESC heart failure.
2021 10; 8(5):4161-4173. doi:
10.1002/ehf2.13509. [PMID: 34235875] - Jaroslava Trnovska, Petr Svoboda, Helena Pelantova, Marek Kuzma, Helena Kratochvilova, Barbora Judita Kasperova, Iveta Dvorakova, Katerina Rosolova, Hana Malinska, Martina Huttl, Irena Markova, Olena Oliyarnyk, Magdalena Melcova, Vojtech Skop, Milos Mraz, Sona Stemberkova-Hubackova, Martin Haluzik. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
International journal of molecular sciences.
2021 Sep; 22(19):. doi:
10.3390/ijms221910606. [PMID: 34638943] - Rafael de la Espriella, Gema Miñana, Enrique Santas, Gonzalo Núñez, Miguel Lorenzo, Eduardo Núñez, Antoni Bayés-Genís, Julio Núñez. Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure.
International journal of cardiology.
2021 09; 339(?):102-105. doi:
10.1016/j.ijcard.2021.06.045. [PMID: 34216708] - Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer, Roland E Schmieder. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Cardiovascular diabetology.
2021 09; 20(1):178. doi:
10.1186/s12933-021-01358-8. [PMID: 34481498] - Mikhail N Kosiborod, Russell Esterline, Remo H M Furtado, Jan Oscarsson, Samvel B Gasparyan, Gary G Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Joan Buenconsejo, Anna Maria Langkilde, Philip Ambery, Fengming Tang, Kensey Gosch, Sheryl L Windsor, Emily E Akin, Ronaldo V P Soares, Diogo D F Moia, Matthew Aboudara, Conrado Roberto Hoffmann Filho, Audes D M Feitosa, Alberto Fonseca, Vishnu Garla, Robert A Gordon, Ali Javaheri, Cristiano P Jaeger, Paulo E Leaes, Michael Nassif, Michael Pursley, Fabio Serra Silveira, Weimar Kunz Sebba Barroso, José Roberto Lazcano Soto, Lilia Nigro Maia, Otavio Berwanger. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
The lancet. Diabetes & endocrinology.
2021 09; 9(9):586-594. doi:
10.1016/s2213-8587(21)00180-7. [PMID: 34302745] - Adel T Osman, Souty M Z Sharkawi, Mohamed I A Hassan, Amira M Abo-Youssef, Ramadan A M Hemeida. Empagliflozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
2021 Sep; 155(?):112406. doi:
10.1016/j.fct.2021.112406. [PMID: 34256053] - Moritz J Hundertmark, Olorunsola F Agbaje, Ruth Coleman, Jyothis T George, Rolf Grempler, Rury R Holman, Hanan Lamlum, Jisoo Lee, Joanne E Milton, Heiko G Niessen, Oliver Rider, Christopher T Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
ESC heart failure.
2021 08; 8(4):2580-2590. doi:
10.1002/ehf2.13406. [PMID: 33960149] - Aline Franco da Rocha, Paulo Sergio Pereira Junior, Gabriela Simonetti Calefi, Guilherme Figueiredo Marquezine, Helena Kaminami Morimoto, Tania Longo Mazzuco, Eliana Cotta de Faria, Mariana Ragassi Urbano, Alexandre Jose Faria Carrilho. Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin.
Endocrine.
2021 08; 73(2):325-330. doi:
10.1007/s12020-021-02730-0. [PMID: 33871793] - Mark Gordon, Patrick Meagher, Kim A Connelly. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
Canadian journal of diabetes.
2021 Aug; 45(6):553-556. doi:
10.1016/j.jcjd.2020.11.003. [PMID: 33388277] - Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, Massimiliano Colzani, Francesca Barzaghi, Andrea Stella, Gianpaolo Zerbini, Gianluca Perseghin, Giovanni Zatti, Cira R T di Gioia. Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy.
Acta diabetologica.
2021 Aug; 58(8):1059-1070. doi:
10.1007/s00592-021-01681-2. [PMID: 33760995] - Ai-Yu Yang, Hung-Chun Chen. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin.
International journal of clinical pharmacy.
2021 Aug; 43(4):1015-1023. doi:
10.1007/s11096-020-01210-1. [PMID: 33258006]